Loading organizations...
§ Private Profile · NY, USA
Digital health company developing connected devices and apps for remote monitoring of respiratory care in asthma and COPD patients.
Based in New York, New York, Cohero Health develops connected health devices and mobile applications for the remote monitoring of respiratory conditions like asthma and COPD. The company's platform integrates HeroTracker inhaler sensors and mSpirometer devices with its BreatheSmart application to track lung function and medication adherence, demonstrating early clinical results that included a 2.5x increase in medication adherence and a 100% reduction in hospitalizations. Prior to its acquisition, the digital health firm secured $2 million in seed funding from investors such as Zaffre Investments and BioAdvance, while deploying its technology across major healthcare providers including Mount Sinai Health System and Dartmouth-Hitchcock Medical Center. In November 2020, the company was acquired by drug delivery manufacturer Aptar Pharma to expand its digital respiratory portfolio. Cohero Health was founded in 2011 by Bard Laabs, David Greenberg, and Melissa Manice.
Cohero Health has raised $15.0M across 2 funding rounds.
Cohero Health has raised $15.0M in total across 2 funding rounds.
Cohero Health has raised $15.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in November 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2016 | $13M Series A | Sean Kearney | BioAdvance, GIS Strategic Ventures, Heitkamp & Thumann Group, P5 Health Ventures, Zaffre Investments | Announced |
| Dec 1, 2015 | $2M Seed | — | BioAdvance, Foundry Group, Fusion Fund, Plug & Play Ventures, Eric Ries, Jaffray Woodriff, StartUp Health, Swanhill Capital, Three Leaf Ventures, Zaffre Investments | Announced |
Cohero Health is a digital health technology company that developed a connected respiratory care platform to empower patients with asthma, COPD, and other respiratory conditions through real-time monitoring of medication adherence and lung function.[1][2][3] Its core products include smart inhaler sensors (HeroTracker), mobile spirometers (Spirometer and cSpirometer), and the BreatheSmart app and platform, which integrate data for patients, caregivers, and providers to improve outcomes and care coordination.[1][3][4] The company served respiratory patients and healthcare providers, addressing poor medication adherence and suboptimal lung function tracking in a market driven by rising respiratory disorders and telehealth trends; it raised $15.6M before being acquired by Aptar Pharma in November 2020, demonstrating strong early growth with deployments reaching over 1 million covered lives.[2][3][4]
Cohero Health was founded in 2013 in New York City as a digital health startup focused on respiratory care innovations.[2][4] While search results reference a 2011 founding by Bard Laabs and David Greenberg for a public health and safety tech provider named Cohero, this appears distinct from the respiratory-focused Cohero Health, which emerged from efforts to create connected devices like medication sensors and spirometers syncing to mobile apps.[7][8] The idea gained traction through pilots, such as a 2014 Mount Sinai deployment for respiratory disease management, and partnerships like the multi-year development of the H&T Presspart eMDI smart inhaler, leading to commercial use in over 25 deployments.[3][6] Pivotal moments included FDA-approved features like mechanical dose counters and HIPAA-compliant data sharing, culminating in its 2020 acquisition by Aptar Pharma, which absorbed its BreatheSmart platform and sensors to expand global digital respiratory solutions.[4]
Cohero Health rode the convergence of IoT wearables, telehealth, and personalized medicine amid surging global respiratory cases (e.g., asthma, COPD), where poor adherence drives 50%+ of exacerbations and billions in costs.[2][3] Its timing aligned with post-2010s remote monitoring booms, accelerated by COVID-19, enabling data-driven care over fragmented analog tools.[2] Market tailwinds include smart inhaler growth via sensors for usage analytics and provider coordination, influencing pharma to embed digital twins in devices.[2][3][4] Post-acquisition, its assets bolster Aptar's global portfolio (e.g., alongside Sonmol, Navia), pushing ecosystem-wide shifts toward integrated diagnostics and patient-centric respiratory tech.[4]
Under Aptar Pharma since 2020, Cohero Health's platform will likely expand into hybrid device-therapy bundles for pharma partners, leveraging global deployments in respiratory and beyond.[4] Trends like AI-enhanced predictive analytics, 5G-enabled real-time monitoring, and value-based care reimbursements will amplify its data flywheel, potentially reducing hospitalizations by empowering proactive management.[2][3] Its influence may evolve from standalone innovator to embedded standard in connected inhalers, scaling impact as personalized health dominates—transforming passive patients into active managers, much like how it disrupted adherence tracking from the start.[1][4]
Cohero Health has raised $15.0M in total across 2 funding rounds.
Cohero Health's investors include Sean Kearney, BioAdvance, GIS Strategic Ventures, Heitkamp & Thumann Group, P5 Health Ventures, Zaffre Investments, Foundry Group, Fusion Fund, Plug & Play Ventures, Eric Ries, Jaffray Woodriff, StartUp Health.